Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
暂无分享,去创建一个
M Baum | J Cuzick | J F Forbes | A Howell | J. Cuzick | A. Howell | J. Forbes | M. Dowsett | A. Buzdar | M. Baum | J. Houghton | M Dowsett | J. Tobias | A Buzdar | J Houghton | G Hoctin-Boes | G Y Locker | J S Tobias | G. Locker | G. Hoctin-Boes
[1] D. Tripathy,et al. Tamoxifen for early breast cancer: An overview of the randomised trials , 1999 .
[2] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.
[3] J. Bryant,et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. , 2001, Journal of the National Cancer Institute.
[4] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[5] M. Dowsett. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses , 2003 .
[6] James N Ingle,et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.